1,386 reports of this reaction
1.7% of all DARBEPOETIN ALFA reports
#9 most reported adverse reaction
DYSPNOEA is the #9 most commonly reported adverse reaction for DARBEPOETIN ALFA, manufactured by Amgen, Inc. There are 1,386 FDA adverse event reports linking DARBEPOETIN ALFA to DYSPNOEA. This represents approximately 1.7% of all 81,618 adverse event reports for this drug.
Patients taking DARBEPOETIN ALFA who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is a less commonly reported adverse event for DARBEPOETIN ALFA, but still significant enough to appear in the safety profile.
In addition to dyspnoea, the following adverse reactions have been reported for DARBEPOETIN ALFA:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 1,386 FDA reports for DARBEPOETIN ALFA. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 1.7% of all adverse event reports for DARBEPOETIN ALFA, making it a notable side effect.
If you experience dyspnoea while taking DARBEPOETIN ALFA, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.